Literature DB >> 2427882

Mechanism of elevated plasma noradrenaline in the course of essential hypertension.

M Esler, G Jennings, B Biviano, G Lambert, G Hasking.   

Abstract

Increased sympathetic nervous system tone may be the initiating pathophysiologic event in some patients with essential hypertension. We estimated sympathetic nervous activity from radiotracer-derived measurements of noradrenaline release to plasma in 34 patients with essential hypertension and 23 subjects with normal blood pressure. The plasma concentration of noradrenaline (32% increased) and the rate of release of noradrenaline to plasma (38% increased) were elevated overall in patients with essential hypertension, largely due to higher noradrenaline release in hypertensive patients aged less than 40 years. Noradrenaline release from the kidneys and heart was elevated; renal noradrenaline spillover was 2.4 times normal in patients aged less than 40 years. Increased renal noradrenaline spillover accounted for 42% and increased cardiac noradrenaline spillover for 4% of the excess total noradrenaline spillover in essential hypertension, leaving 54% unexplained. Total noradrenaline spillover to plasma was normal in hypertensive patients aged 60 years and over. The plasma noradrenaline concentration was similar in younger and older hypertensive patients, despite lower noradrenaline release in the latter due to an age-dependent fall in noradrenaline plasma clearance in essential hypertension. Cardiorenal sympathetic nervous system tone appears to be increased in essential hypertension, particularly in younger patients. This contributes substantially to the higher plasma noradrenaline values found.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427882     DOI: 10.1097/00005344-198608005-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  28 in total

Review 1.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 2.  Premise, promise, and potential limitations of invasive devices to treat hypertension.

Authors:  Elizabeth A Martin; Ronald G Victor
Journal:  Curr Cardiol Rep       Date:  2011-02       Impact factor: 2.931

Review 3.  Selective alpha 1-adrenoreceptor blockers in the treatment of hypertension: should we be using them more?

Authors:  M Ligueros; R Unwin; M Wilkins
Journal:  Clin Auton Res       Date:  1991-09       Impact factor: 4.435

Review 4.  Renal sympathetic nerve activity in the development of hypertension.

Authors:  Simon C Malpas; Rohit Ramchandra; Sarah-Jane Guild; Fiona McBryde; Carolyn J Barrett
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 5.  Obstructive sleep apnea: the new cardiovascular disease. Part I: Obstructive sleep apnea and the pathogenesis of vascular disease.

Authors:  Rami Khayat; Brian Patt; Don Hayes
Journal:  Heart Fail Rev       Date:  2008-09-20       Impact factor: 4.214

6.  123I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity?

Authors:  Christopher George; Pradeep G Bhambhvani; Suzanne Oparil
Journal:  J Nucl Cardiol       Date:  2016-12-30       Impact factor: 5.952

Review 7.  [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].

Authors:  M Wallbach; M J Koziolek; R Wachter
Journal:  Internist (Berl)       Date:  2018-10       Impact factor: 0.743

Review 8.  Sympathoneural and adrenomedullary responses to mental stress.

Authors:  Jason R Carter; David S Goldstein
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

9.  Comparison of cardiac versus vascular reactors and ethnic groups in plasma epinephrine and norepinephrine responses to stress.

Authors:  K C Light; J R Turner; A L Hinderliter; S S Girdler; A Sherwood
Journal:  Int J Behav Med       Date:  1994

Review 10.  Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.

Authors:  Alexandre Persu; Sverre Kjeldsen; Jan A Staessen; Michel Azizi
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.